Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

About this update from Spero Therapeutics, Inc.

CAMBRIDGE, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced the appointment of Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer. Dr. Zack will lead Spero's clinical development strategy and organization as the Company advances its immunology program. "We are delighted to welcome Deb to Spero at an important time as we initiate clinical development of SP001," said Esther Rajavelu, President and Chief Executive Officer of Spero "She brings deep expertise in rheumatology and immunology along with firsthand experience advancing innovative therapies for autoimmune diseases. Deb's leadership will be invaluable as we advance our clinical strategy with the goal of delivering meaningful therapies for patients with significant unmet medical needs." Dr. Zack is a board-certified rheumatologist with a Ph.D. in immunology and extensive drug development experience spanning research, clinical development, and medical affairs. At Amgen, she served as Global Development Lead for Enbrel and held additional roles spanning preclinical research, clinical development, and medical affairs. Most recently, Dr. Zack served as Chief Medical Officer of Exagen Inc., and before that she held clinical leadership roles at Xencor Inc., and in the Biotherapeutics Development Unit at Novartis. Before these roles, Dr. Zack served as an associate professor at UCLA for 10 years, treating rheumatology patients and conducting research in molecular immunology. Dr. Zack received her M.D. and Ph.D. from the University of Texas Southwestern Medical School in Dallas, and she completed her residency and rheumatology fellowship at the UCLA School of Medicine. "I am thrilled to join Spero at such a pivotal time in the Company's evolution," said Dr. Zack. "Spero has set a strong foundation with SP001, targeting CD40 ligand, as its lead asset in immunology. The inhibition of this target, which modulates both B-cell and T-cell activation, has the potential to address multiple drivers of immune-mediated diseases, such as IgG4-RD and the opportunity to evaluate and potentially advance this mechanism is particularly compelling. I look forward to working alongside the talented Spero team to advance SP001 and help shape a disciplined c...

View stock analysis, news, and events for Spero Therapeutics, Inc.